Genetic unexceptionalism: Clinician accounts of genetic testing for familial hypercholesterolaemia

Social Science and Medicine

Volumn 71, Issue 5, 2010, Pages 910-917

  Will, Catherine M ^a   Armstrong, David ^b   Marteau, Theresa M ^b  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cholesterol; Diagnosis; DNA testing; Genetic exceptionalism; Heart disease; Hypercholesterolaemia; Professionals; UK

Indexed keywords

CHOLESTEROL; DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; DETECTION METHOD; DNA FINGERPRINTING; GENETICS; HEALTH RISK; HEALTH WORKER; HOSPITAL SECTOR; RISK FACTOR; TESTING METHOD;

ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DELAYED DIAGNOSIS; DIAGNOSTIC VALUE; DRUG USE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY; GENERAL PRACTITIONER; GENETIC SCREENING; HUMAN; INFORMATION; LIFESTYLE MODIFICATION; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; NURSE; PATIENT REFERRAL; SEMI STRUCTURED INTERVIEW; UNITED KINGDOM;

UNITED KINGDOM;

EID: 77955094051     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.socscimed.2010.05.018     Document Type: Article

References (38)

1. Berg M. The construction of medical disposals. Medical sociology and medical problem solving in clinical practice. Sociology of Health and Illness 1992, 14:151-180.
2. Bharadwaj A. Uncertain risk: genetic screening for susceptibility to haemochromatosis. Health, Risk and Society 2002, 4:227-240.
3. Bourret P. BRCA patients and clinical collectives: new configurations of action in cancer genetics practices. Social Studies of Science 2005, 35:41-68.
4. Cox S.M., Starzomski R.C. Genes and geneticization? The social construction of autosomal dominant polycystic kidney disease. New Genetics and Society 2003, 23:137-166.
5. Davison C., Davey Smith G., Frankel S. Lay epidemiology and the prevention paradox: the implications of coronary candidacy for health education. Sociology of Health & Illness 1991, 13(1):1-19.
6. Featherstone K., Cox S.M., Starzomski R.C. Genes and geneticization? The social construction of autosomal dominant polycystic kidney disease. New Genetics and Society 2004, 23:137-166.
7. Hall R., Saukko P., Evans P., Qureshi N., Humphries S. Assessing family history of heart disease in primary care consultations: a qualitative study. Family Practice 2007, 24:435-442.
8. Hallowell N. Doing the right thing: genetic risk and responsibility. Sociology of Health & Illness 1999, 21:597-621.
9. Hallowell N. Varieties of suffering: living with the risk of ovarian cancer. Health, Risk and Society 2006, 8:9-26.
10. Hallowell N., Cooke S., Crawford G., Lucassen A., Parker M. Distinguishing research from clinical care in cancer genetics: theoretical justifications and practical strategies. Social Science & Medicine 2009, 68:2010-2017.
11. Hedgecoe A. Expansion and uncertainty: cystic fibrosis, classification and genetics. Sociology of Health and Illness 2003, 25(1):50-70.
12. Hedgecoe A. The politics of personalised medicine 2004, Cambridge University Press, Cambridge.
13. Holtzman N.A., Marteau T.M. Will genetics revolutionize medicine?. New England Journal of Medicine 2000, 343:141-144.
14. Horstman K. Lifestyle, genes and cholesterol; new struggles about responsibility and solidarity. Genetics from laboratory to society: Societal learning as an alternative to regulation 2007, 64-89. Palgrave Macmillan, Basingstoke. G. De Vries, K. Horstman (Eds.).
15. Kerr A. Giving up on geneticization: a comment on Hedgecoe's expansion and uncertainty: cystic fibrosis, classification and genetics. Sociology of Health and Illness 2004, 26(1):102-106.
16. Latimer J., Featherstone K., Atkinson P., Clarke A., Pilz D.T., Shaw A. Rebirthing the clinic: the interaction of clinical judgment and genetic technology in the production of medical science. Science, Technology and Human Values 2006, 31:599-629.
17. Marks D., Thorogood M., Farrer J.M., Humpries S.E. Census of clinics providing specialist lipid services in the United Kingdom. Journal of Public Health 2004, 26:353-354.
18. Marteau T.M., Weinman J. Self-regulation and the behavioural response to DNA risk information: a theoretical analysis and framework for future research. Social Science & Medicine 2006, 62:1360-1368.
19. Miller F.A., Ahern C., Ogilvie J., Giacomini M., Schwartz L. Ruling in and ruling out: implications of molecular genetics diagnoses for disease classification. Social Science & Medicine 2005, 61:2536-2545.
20. Murray T. Genetic exceptionalism and 'future diaries': is genetic information different from other medical information. Genetic Secrets: Protecting privacy and confidentiality in the genetic era 1997, Yale University Press, New Haven. Rothstein (Ed.).
21. National Institute of Health and Clinical Excellence Familial hypercholesterolaemia. NICE guideline 71. Developed by the National Collaborating Centre for primary care 2008, National Institute for Health and Clinical Excellence, London.
22. National Institute of Health and Clinical Excellence (NICE) Lipid modification. NICE guideline 67. Developed by the National Collaborating Centre for primary care 2008, National Institute for Health and Clinical Excellence, London.
23. Novas C., Rose N. Genetic risk and the birth of the somatic individual. Economy and Society 2000, 29:485-513.
24. Prior L. Risk, rationing and genetics: all categories have wheels. Sociology of Health and Illness 2001, 23(5):570-593.
25. Rose H. From hype to mothballs in four years: troubles in the development of large-scale DNA biobanks in Europe. Community Genetics 2006, 9:184-189.
26. Ross L.F. Genetic exeptionalism vs paradigm shift: lessons from HIV. Journal of Law, Medicine and Ethics 2001, 29:141-148.
27. Saukko P., Richards S., Shepherd M., Campbell J. Are genetic tests exceptional? Lessons from a qualitative study on thrombophilia. Social Science & Medicine 2006, 63:1947-1959.
28. Scientific Steering Committee on behalf of the Simon Broome Register Group Risk of fatal coronary heart disease in familial hypercholesterolaemia. British Medical Journal 1991, 303:893-896.
29. Scott S., Prior L., Wood F., Gray J. Repositioning the patient: the implications of being 'at risk'. Social Science & Medicine 2005, 60(8):1869-1879.
30. Senior V., Marteau T., Peters T. Will genetic testing for predisposition for disease result in fatalism? A qualitative study of parents responses to neonatal screening for familial hypercholesterolaemia. Social Science & Medicine 1999, 48:1857-1860.
31. Senior V., Smith K., Michie S., Marteau T.M. Making sense of risk: an interpretative phenomenological analysis of vulnerability to heart disease. Journal of Health Psychology 2002, 7:157-168.
32. Vailly J. The expansion of abnormality and the biomedical norm: neonatal screening, prenatal diagnosis and cystic fibrosis in France. Social Science & Medicine 2008, 66:2532-2543.
33. Walter F.M., Emery J.D., Braithwaite D.K., Marteau T.M. Lay understanding of familial risk of common chronic diseases: a systematic review and synthesis of qualitative research. Annals of Family Medicine 2004, 2:583-594.
34. Weiner K. The tenacity of the coronary candidate: how people with familial hypercholesterolaemia construct raised cholesterol and coronary heart disease. Health: An Interdisciplinary Journal for the Social Study of Health, Illness and Medicine 2009, 13:407-427.
35. Weiner K., Durrington P.N. Patients' understandings and experiences of familial hypercholesterolaemia. Community Genetics 2008, 11:273-282.
36. Weiner K., Martin P. A genetic future for coronary heart disease?. Sociology of Health and Illness 2008, 30:380-395.
37. Wierzbicki, A., Dermont, N., & Ratcliffe, C (on behalf of the Medical Scientific and Research Committee Heart UK) (2008). UK Annual Conference, June 2008 (with financial support from Genzyme).
38. Will C.M. Arguing about the evidence: readers, writers and inscription devices in coronary heart disease risk assessment. Sociology of Health & Illness 2005, 27:780-801.